Semaglutide Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 20 to 24 weeks to reach full therapeutic dose; maintenance continues beyond that without a defined end point
• Frequency: Once weekly, every 7 days, on the same chosen day each week
• Common delivery routes: Subcutaneous injection (abdomen, thigh, upper arm)
• Key timing notes: Consistency of day matters more than time of day; the 7 to 9 day dosing window is the effective interval, and going beyond 9 days reduces therapeutic effect

Who This Protocol Is For

Semaglutide draws two distinct groups of people. The first is anyone working toward meaningful, sustained fat loss: people whose primary goal includes improving metabolic health alongside fat loss, and who want a pharmacological tool that addresses the appetite and food-noise component directly. The second is people managing type 2 diabetes, where semaglutide's effects on blood sugar regulation are the primary goal.

Those two goals overlap more than people expect. The appetite suppression that makes semaglutide effective for weight loss also benefits metabolic health, and the blood sugar modulation that matters for diabetes also supports a better body composition trajectory. Where the protocols differ is in the target dose and the formulation most commonly used.

Experience level matters differently here than with research peptide cycles. Most people starting semaglutide do so under some form of medical supervision, and the titration protocol is standardized rather than user-customized. What varies by individual tolerance is how quickly someone moves through titration steps, whether they need to hold a step longer than four weeks, and what maintenance dose they ultimately land on. Those are the real individual variables, and they play out over months.

Delivery method is less of a variable here than with many compounds. FDA-approved forms come in pre-filled auto-injector pens designed to remove injection complexity. Compounded versions use multi-dose vials that require the user to draw and measure their own dose, which introduces a meaningful layer of error risk. That distinction matters for how a protocol is run in practice.

How Is a Semaglutide Cycle Structured?

The structure of a semaglutide protocol is defined by its titration. Unlike most research peptides that start at a target dose and run for a fixed number of weeks, semaglutide begins well below its effective range and climbs through a series of steps, each held for four weeks, until reaching the maintenance dose. The entire arc from first injection to full therapeutic dose takes 16 weeks. Most protocols then continue at that maintenance dose for at least another 4 to 8 weeks, putting the typical standard course at 20 to 24 weeks.

Think of the titration as a ramp rather than an on switch. The body needs time to adapt to GLP-1 receptor agonism, the process by which semaglutide mimics a gut hormone that signals fullness and regulates appetite, particularly in the gastrointestinal tract. Rushing the ramp is the single most common structural mistake in a semaglutide protocol and reliably produces side effects that patient adaptation over four weeks would have avoided.

There is no defined off-cycle break in a standard semaglutide protocol. The compound does not create receptor tolerance over time in the way some other peptide classes do. Once someone reaches their goal weight, the conversation shifts to reducing the maintenance dose to the lowest level that keeps results stable, not to stopping the protocol entirely. The phases are: initiation, titration, maintenance at full dose, and for many people a long-term reduced maintenance phase after the primary goal is reached. Full phase detail is in the Loading and Maintenance Phases section.

How Your Dose Is Determined

What moves a semaglutide dose:

• Your goal: Weight management and type 2 diabetes management reach different target doses. Weight management protocols typically aim for the highest approved maintenance dose. Diabetes management targets a lower range. Within weight management, where someone lands depends on how much appetite suppression is needed and how well they tolerate each step in the titration.
• Experience level: Tolerance to GLP-1 agonism varies considerably from person to person. Someone who moves through each titration step without meaningful side effects advances on schedule. Someone with persistent nausea or GI discomfort at a given step holds that step for an additional four weeks before attempting to move up. Where they ultimately land on the maintenance dose reflects individual tolerance, not a fixed target.
• Delivery route: All FDA-approved semaglutide formulations use subcutaneous injection. Compounded versions also use the subcutaneous route but introduce concentration variability across different suppliers, which directly affects how a dose translates between products. The dose and the concentration are not the same number, and confusing them is the source of the most serious errors with this compound.
• Individual response: Two people with the same goal and the same starting point can land at different maintenance doses based on how robustly they respond to GLP-1 agonism. Someone who reaches their weight target at a lower titration step may maintain there rather than continuing to escalate.

The maintenance dose is determined through the titration process itself, not decided in advance. Some people respond well at an earlier step and stay there. Others need to reach the higher end of the approved range for meaningful appetite suppression. There is also an FDA-recognized alternative maintenance dose for people who cannot tolerate the highest approved level. The point is that the protocol finds the right dose for the individual, and that process takes the full titration arc to complete.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your primary goal, your individual tolerance at each titration step, and your delivery method, and builds your semaglutide protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take Semaglutide?

Semaglutide is taken once every seven days. That is not a rough guideline: it is the frequency the compound's pharmacokinetics are built around. Semaglutide has a half-life of approximately seven days, which means a single weekly injection maintains therapeutic drug levels across the full dosing interval. Steady-state concentration builds over the first four to five weeks of continuous weekly dosing and is what supports consistent appetite suppression once established.

Picking a consistent day of the week and sticking with it matters more than the specific time of day. The injection can be given at any time, with or without food, but keeping the same day each week removes a variable that otherwise leads to late or missed injections. Many people anchor it to a fixed morning routine.

The effective dosing window is seven to nine days. Going beyond nine days reduces therapeutic effect as drug levels fall below the range that maintains appetite suppression. Shortening the interval below seven days does not add benefit and may increase side effect load. Biweekly dosing, one injection every other week, is off-label and not supported by clinical evidence for efficacy.

Injection sites are rotated with each administration across three areas: the abdomen, the thigh, and the upper arm. Repeatedly injecting the same location can cause tissue changes that affect absorption over time, so site rotation is a practical protocol habit, not optional.

Loading and Maintenance Phases

The titration phase is the defining structural feature of a semaglutide protocol. It begins at the lowest approved dose and steps upward every four weeks until the full therapeutic maintenance dose is reached.

One point that surprises many people: the initiation dose is not higher than maintenance. It is the opposite. The starting step is a low introductory dose there specifically to let the body begin adapting to GLP-1 agonism before the dose climbs into the range where real appetite suppression takes hold. It produces minimal weight loss or glycemic effect by design.

Each subsequent step builds on the prior one. By the second and third titration steps, appetite suppression becomes more noticeable and consistent for most users. The fourth step transitions toward the maintenance level. At that point, individual tolerance assessment matters: if someone cannot comfortably tolerate this step, they hold it for an additional four weeks rather than pushing forward.

The maintenance phase begins when the target dose is reached and held. For weight management, this is the highest approved level unless tolerance prevents reaching it, in which case the prior step becomes the maintenance dose. The maintenance phase has no fixed end point and continues as long as the therapeutic goal requires it.

After reaching a goal weight, the next phase is a gradual reduction to the lowest dose that keeps appetite suppression and weight stability intact. This post-goal phase uses lower steps from the titration range and is individualized based on what maintains results without excess medication load. Abrupt discontinuation after reaching goal weight is not the standard approach, because weight regain is the consistent outcome of stopping without a managed transition.

Off-Cycle Considerations

There is no standard off-cycle break in a semaglutide protocol. Unlike research peptides where cycling off allows receptor sensitivity to reset, semaglutide does not have a desensitization concern that warrants a planned break. The compound is designed for continuous, long-term use, and the clinical evidence establishing its efficacy was built on uninterrupted weekly dosing.

Some practitioners have explored intermittent use, pausing for a period before restarting, usually for cost or side-effect management reasons. No published research we are aware of has directly compared intermittent to continuous use on outcomes, so that approach remains genuinely uncharted territory.

The clearest consequence of stopping semaglutide after reaching goal weight is weight regain. The standard approach is a managed transition to a reduced maintenance dose rather than abrupt discontinuation. That dose-reduction phase is the closest thing this protocol has to an off-cycle, and it is better understood as a dose optimization step than a break.

The practical frame: do not plan semaglutide like a short peptide cycle with a defined on and off. Plan it as a long-term protocol with a titration arc, a full maintenance phase, and then a deliberate conversation about dose reduction once the primary goal is met.

What to Expect Week by Week

• Week 1 to 2: Responses in the first week vary widely. Fast responders notice a quieting of food noise, the constant background mental pull toward eating and cravings, within hours of the first injection. Some report modest weight change in the first week. Others feel essentially nothing at this stage, which is also normal. Mild nausea, gas, and GI discomfort are commonly reported, particularly after eating rich or fatty foods.
• Week 3 to 4: Appetite suppression becomes more consistent for most people. Fullness arrives faster at meals, and the drive toward calorie-dense foods tends to soften. GI side effects often begin settling as the body adjusts, though they may not have resolved fully for everyone by week four.
• Week 5 to 8: The dose steps up for the first time at week five. For most people, this is where appetite suppression becomes unmistakably present. Weight loss becomes more consistent and linear during this window. Food intake naturally decreases as appetite regulation improves, without the same willpower expenditure that caloric restriction demands on its own.
• Month 3 and beyond: Titration continues toward the therapeutic maintenance dose. Weight loss at this stage commonly tracks in the range of a few pounds per month on average, with significant individual variation based on diet, activity, and dose reached. A 2021 New England Journal of Medicine trial (Wilding et al.) of 1,961 participants found approximately 15 to 16 percent total body weight loss at 68 weeks of continuous weekly dosing at the full maintenance dose, with more than 86 percent of participants losing at least 5 percent of their body weight. That is the realistic picture of what a well-structured, fully-titrated protocol commonly produces over the long arc of consistent use.

Individual results vary substantially based on genetics, diet, physical activity, the specific dose reached in titration, and individual GLP-1 response. These timelines are commonly reported ranges drawn from clinical data and real-world protocols, not predictions or guarantees.

Common Protocol Mistakes

Rushing the titration. Every four-week hold in the titration exists to let the body adapt before the dose climbs. Moving up early because side effects seem manageable or because progress feels slow is the most common structural error. Side effects that appear manageable at one step can become genuinely disruptive when a higher dose is added before adaptation is complete.

Treating the initiation dose as the working dose. The starting step produces minimal appetite suppression by design. Users who expect significant results at this step and interpret the absence of dramatic change as the compound not working sometimes abandon the protocol before reaching the dose range where real effects appear. The first four weeks are about tolerability, not outcomes.

Dosing errors with compounded versions. The FDA has issued specific alerts about dosing errors associated with compounded semaglutide. Compounded vials require users to draw and measure their own dose, and concentration varies across suppliers. Drawing too much from a multi-dose vial, confusing milligrams with milliliters with units, and using a syringe calibrated for a different scale are all errors that have resulted in people receiving many times the intended dose. Using an FDA-approved auto-injector pen eliminates this risk category. When a compounded version is what is available, explicit provider instruction on measurement, including the correct syringe for that specific product, is not optional.

Expecting fast, linear results. Semaglutide works on a timeframe of months. The first titration step is not therapeutic for weight loss. Meaningful appetite suppression often does not solidify until the second or third step. Comparing a week-three experience to clinical outcome data measured at 68 weeks is the wrong benchmark.

Stopping abruptly after reaching goal weight. The therapeutic effect of semaglutide requires continued use. Stopping after hitting a weight target typically results in weight regain. The standard approach is a transition to a reduced maintenance dose, not discontinuation.

Ignoring injection site rotation. Injecting the same location repeatedly affects absorption over time. Rotating across the abdomen, thigh, and upper arm with each injection is a straightforward habit that protects protocol quality.

Semaglutide is FDA-approved for weight management (in the FDA-approved weight management formulation) and type 2 diabetes (in the FDA-approved diabetes formulation). It is not approved for performance enhancement or anabolic cycling.

Frequently Asked Questions

How long is a typical semaglutide cycle?

The titration phase runs 16 weeks, with each of the four dose steps held for four weeks before advancing. Most standard protocols continue for another 4 to 8 weeks at the full therapeutic dose after titration is complete, putting the typical initial course at 20 to 24 weeks. Beyond that, maintenance continues without a defined end point, with individual length shaped by goals and provider guidance.

How often do you take semaglutide?

Once every seven days, on the same chosen day each week. Semaglutide's half-life of approximately seven days is what makes weekly dosing both sufficient and optimal. The effective dosing window is seven to nine days; going beyond nine days reduces therapeutic effect as drug levels fall below the range that sustains appetite suppression.

Does semaglutide need a loading phase?

Not in the traditional sense. The initiation dose is the lowest step in the titration, there specifically for tolerability rather than to front-load the system. The dose starts low and climbs gradually over 16 weeks to the therapeutic maintenance level, which is the opposite of a high-dose loading approach.

Do you need to cycle off semaglutide?

Standard protocols do not include planned off-cycle breaks. There is no receptor desensitization concern that warrants cycling off the compound. After reaching a goal weight, the standard approach is a transition to a reduced maintenance dose rather than stopping, because weight regain is the consistent outcome of abrupt discontinuation.

What happens if you miss a semaglutide injection?

Given semaglutide's seven-day half-life, a single missed injection does not derail the protocol. If the missed dose is caught within a short window after the scheduled day, it can be taken as soon as noticed and the regular schedule resumed from that point. If too much time has passed, the missed dose is skipped and the next scheduled injection follows the original calendar. Double dosing to catch up is not part of the protocol.

Can semaglutide be used without a prescribing provider?

FDA-approved semaglutide is a prescription medication, available in both the weight management formulation and the diabetes formulation. Compounded versions exist through various channels, but the FDA has flagged compounded semaglutide specifically for dosing error risks and does not review compounded versions for safety or efficacy. The complexity of accurately measuring and administering compounded vials makes provider involvement genuinely important, not a formality.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and real-world protocols for semaglutide in one place.